LiBBY — Life's End Benefits of cannaBidiol and tetrahYdrocannabinol — tested a THC/CBD oil for strong agitation in hospice-eligible dementia. It lowered agitation scores more than placebo, and caregivers can ask the care team about fit, safety, and next research.
Hospice-eligible means a person has advanced illness and qualifies for hospice comfort care. Agitation here means restlessness, shouting, hitting, pacing, or resisting care that causes distress. The Phase 2 study focused on that late-stage group.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did LiBBY test and who joined?
- How much did agitation change?
- Was it tolerated in frail patients?
- What can caregivers ask the care team?
What did LiBBY test and who joined?
The study is listed as a randomized, double-blind, placebo-controlled trial for clinically significant agitation in hospice-eligible dementia patients in the ClinicalTrials.gov record. That design means neither families nor staff knew who received active oil or placebo. About 120 adults with Alzheimer's disease or other dementias took part, according to Medical Express/Pennington Biomedical. Visits happened at homes or residences across 10 U.S.
centers. That home-based approach matters for frail people who cannot travel to clinics. Participants received MediPharm Labs' oral rapid-acting T2:C100 oil, according to NeurologyLive in its July 2026 trial report. Week 1 used 2 mg THC plus 100 mg CBD per dose. Weeks 2 through 12 used 4 mg THC plus 200 mg CBD twice daily versus placebo.
How much did agitation change?
Dr. Jacobo Mintzer reported that LiBBY met its main goal at week 2, according to MIMS Hong Kong in its August 2026 news update. Scores on the Cohen-Mansfield Agitation Inventory fell 10.61 points with THC/CBD versus 4.35 points with placebo. That inventory is a staff checklist of agitated actions, such as pacing, yelling, and grabbing. The gap appeared early and matters because distress can rise fast near the end of life.
A larger drop means fewer frequent or severe behaviors during daily care. Families may notice calmer meals, bathing, bedtime, and visits. By 12 weeks, about 87-90% of treated patients showed overall agitation improvement versus about 23% on placebo, according to Neuroscience News. Benefit also continued in a completed 12-week open-label extension, when all participants could receive active treatment. Longer follow-up helps families look beyond a short early win.
Was it tolerated in frail patients?
Overall adverse-event rates were similar to placebo, according to a ScienMag summary of the topline results. Investigators judged none of the serious adverse events related to study medication. That pattern supports tolerability in frail end-of-life patients. Similar rates do not mean zero risk.
Frail adults often take many drugs and react strongly to sleepiness, low blood pressure, falls, confusion, or appetite change. Hospice teams watch drug interactions, swallowing, balance, and alertness closely. Topline results were first presented at the Alzheimer's Association International Conference 2026 in London and online, according to Pennington Biomedical Research Center. The session focused on developing topics in end-of-life dementia care. Conference presentation means outside review and full publication may still follow.
What can caregivers ask the care team?
The work was led by University of Southern California Keck investigators and funded mainly by the National Institute on Aging/NIH, with added Alzheimer's Association support, according to the MediPharm Labs Q2 2026 report. The purified medical oil differs from dispensary cannabis. Caregivers should ask the hospice or dementia care team rather than substitute consumer products, and larger Phase 3 data are still needed.
Bring the current behavior record, drug list, and goals for comfort. Ask what a trial result means for this person, not for dementia in general. Use plain questions and write down the answers.
- Would this approach fit my person's agitation type, health, and hospice plan?
- What benefits and side effects should we watch for in the first two weeks?
- How would it affect sleep, falls, mood drugs, pain drugs, and swallowing?
- What non-drug steps should continue, and when should we call the team?
- Are other trials or approved options available, and what happens next?
You Might Also Like
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Questions Family Caregivers Can Ask About the Research
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: Questions Family Caregivers Can Ask About the Research
- Strengths-Based Dementia Care in the 2026 NIA Report: Questions Family Caregivers Can Ask Local Care Programs
